ArticleAntimicrobial agents and chemotherapy2016
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Infectious diseases and therapy · 2025Review
- Epidemiological trends and disparities in the global burden of bacterial skin diseases among children and adolescents from 1990 to 2021: an analysis based on GBD 2021.BMC pediatrics · 2025Article
- The future approach for the management of acute bacterial skin and skin structure infections.Current opinion in infectious diseases · 2025Review
- Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?Heliyon · 2025Article
- What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2024Article
- Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria.Annals of clinical microbiology and antimicrobials · 2024Article
- Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin.Infectious diseases and therapy · 2023Article
- Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis.Pathogens (Basel, Switzerland) · 2023Review
- The role of long-acting antibiotics in the clinical practice: a narrative review.Le infezioni in medicina · 2023Review
- Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.Open forum infectious diseases · 2022Article
- Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.The Journal of antimicrobial chemotherapy · 2021Article
- Two Novel Semisynthetic Lipoglycopeptides Active againstPharmaceuticals (Basel, Switzerland) · 2021Article
- Distinct Effectiveness of Oritavancin against Tolerance-InducedAntibiotics (Basel, Switzerland) · 2020Article
- Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms.Antimicrobial agents and chemotherapy · 2020Article
- Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.Antimicrobial agents and chemotherapy · 2019Article
- Novel Miniature Membrane Active Lipopeptidomimetics against Planktonic and Biofilm Embedded Methicillin-Resistant Staphylococcus aureus.Scientific reports · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibacterial agents that kill nondividing bacteria may be of utility in treating persistent infections. Oritavancin and dalbavancin are bactericidal lipoglycopeptides that are approved for acute bacterial skin and skin structure infections in adults caused by susceptible Gram-positive pathogens. Using time-kill methodology, we demonstrate that oritavancin exerts bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates that are maintained in a nondividing state in vitro, whereas dalbavancin and the glycopeptide vancomycin do not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.